Retatrutide: The Triple Agonist Peptide Targeting GLP-1, GIP, and Glucagon Receptors
Review examines retatrutide, the first triple GLP-1/GIP/glucagon receptor agonist, which achieved up to 24% weight loss in trials and represents the next frontier of metabolic peptide therapy.
Quick Facts
What This Study Found
Retatrutide achieved up to ~24% weight loss as a triple GLP-1/GIP/glucagon agonist, with acceptable safety and metabolic benefits beyond what dual agonists provide.
Key Numbers
Databases searched through May 2024. Specific weight loss percentages and number of included trials were analyzed but not detailed in available abstract.
How They Did This
Review of retatrutide clinical trial data, triple receptor mechanism, efficacy and safety outcomes.
Why This Research Matters
24% weight loss approaches bariatric surgery results without surgery. If retatrutide proves safe in larger trials, it could become the most effective non-surgical obesity treatment ever developed.
The Bigger Picture
The progression from single GLP-1 drugs (semaglutide, ~15%) to dual agonists (tirzepatide, ~21%) to triple agonists (retatrutide, ~24%) shows how activating additional metabolic receptors incrementally improves weight loss. Retatrutide represents the current peak of peptide metabolic drug design.
What This Study Doesn't Tell Us
Phase 2 data showed the 24% weight loss; phase 3 results still pending. GI side effects may be more common with triple agonism. Glucagon activation raises theoretical concerns about blood sugar in some patients. Long-term safety unknown.
Questions This Raises
- ?Will phase 3 trials confirm the ~24% weight loss seen in phase 2?
- ?Does triple agonism have a meaningfully different side effect profile than dual agonism?
- ?Could retatrutide replace bariatric surgery for many patients?
Trust & Context
- Key Stat:
- ~24% weight loss Retatrutide triple agonist approaches bariatric surgery-level weight loss through simultaneous GLP-1, GIP, and glucagon receptor activation
- Evidence Grade:
- Moderate evidence: promising phase 2 data reviewed; phase 3 trials ongoing for definitive efficacy and safety confirmation.
- Study Age:
- Published in 2025. Covers the latest clinical data for this first-in-class triple agonist.
- Original Title:
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
- Published In:
- Proceedings (Baylor University. Medical Center), 38(3), 291-303 (2025)
- Authors:
- Abdrabou Abouelmagd, Alaa(2), Abdelrehim, Amro Mamdouh, Bashir, Mohamed Nabih, Abdelsalam, Fares, Marey, Ahmed, Tanas, Yousef, Abuklish, Duha Milad, Belal, Mohamed Mohamed
- Database ID:
- RPEP-09740
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Is retatrutide better than semaglutide or tirzepatide?
Phase 2 data suggests retatrutide achieves more weight loss (~24%) than semaglutide (~15%) or tirzepatide (~21%) by activating an additional receptor (glucagon). However, phase 3 results are needed for definitive comparison, and side effects may differ.
When will retatrutide be available?
Retatrutide is in phase 3 clinical trials. If successful, it could receive regulatory approval within approximately 1-2 years. Keep in mind that approval timelines are uncertain.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09740APA
Abdrabou Abouelmagd, Alaa; Abdelrehim, Amro Mamdouh; Bashir, Mohamed Nabih; Abdelsalam, Fares; Marey, Ahmed; Tanas, Yousef; Abuklish, Duha Milad; Belal, Mohamed Mohamed. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.. Proceedings (Baylor University. Medical Center), 38(3), 291-303. https://doi.org/10.1080/08998280.2025.2456441
MLA
Abdrabou Abouelmagd, Alaa, et al. "Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.." Proceedings (Baylor University. Medical Center), 2025. https://doi.org/10.1080/08998280.2025.2456441
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ..." RPEP-09740. Retrieved from https://rethinkpeptides.com/research/abdrabou-2025-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.